伴有JAK2 V617F突变阳性的急性髓系白血病1例报告并文献复习  

The JAK2 V617F mutation in acute myeloid leukemia:a case report and literature review

作　　者：焦愿愿 李佳[1] 张嵘[1] 刘卓刚[1] 王洪涛[1] 

机构地区：[1]中国医科大学附属盛京医院血液病治疗中心,沈阳110004

出　　处：《临床血液学杂志》2018年第2期222-224,共3页Journal of Clinical Hematology

摘　　要：急性髓系白血病（acute myeloid leukemia,AML）是一种造血干细胞的恶性克隆性疾病。AML是由髓系细胞分化发育过程中造血干细胞恶性转化而来,同时也可继发于肿瘤相关疾病的化疗、放疗或由其他血液相关疾病如骨髓增生异常综合征、骨髓增殖性肿瘤（MPN）转化而来[1]。现报告1例伴有JAK2V617F突变阳性的AML患者资料并复习相关文献,对伴有JAK2V617F突变阳性的AML的发病机制和预后进行探讨。We describe a case of acute myeloid leukemia（AML）patient with JAK2 V617 Fpositive mutation.AML originated from malignant transformed hematopoietic stem cells during the process of cell differentiation and development.Furthermore,AML can be secondary to chemotherapy and radiotherapy for solid tumor or other related hematopoietic system diseases,such as myelodysplastic syndrome and myeloproliferative neoplasms（MPN）.The JAK2 V617 Fmutation has recently been reported in MPN,but the JAK2 V617 F mutation in AML patients is rarely reported.

关 键 词：急性髓系白血病 JAK2 V617F 

分 类 号：R733.71[医药卫生—肿瘤]